Literature DB >> 14719797

Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme.

Joachim Bär1, Anja Weber, Torsten Hoffmann, Jörg Stork, Michael Wermann, Leona Wagner, Susanne Aust, Bernd Gerhartz, Hans-Ulrich Demuth.   

Abstract

Dipeptidyl peptidase IV/CD26 (DP IV) is a multifunctional serine protease cleaving off dipeptides from the N-terminus of peptides. The enzyme is expressed on the surface of epithelial and endothelial cells as a type II transmembrane protein. However, a soluble form of DP IV is also present in body fluids. Large scale expression of soluble human recombinant His(6)-37-766 DP IV, using the methylotrophic yeast Pichia pastoris, yielded 1.7 mg DP IV protein per litre of fermentation supernatant. The characterisation of recombinant DP IV confirmed proper folding and glycosylation similar to DP IV purified from porcine kidney. Kinetic comparison of both proteins using short synthetic substrates and inhibitors revealed similar characteristics. However, interaction analysis of both proteins with the gastrointestinal hormone GLP-1(7-36) resulted in significantly different binding constants for the human and the porcine enzyme (Kd = 153.0 +/- 17.0 microM and Kd = 33.4 +/- 2.2 microM, respectively). In contrast, the enzyme adenosine deaminase binds stronger to human than to porcine DP IV (Kd = 2.15 +/- 0.18 nM and Kd = 7.38 +/- 0.54 nM, respectively). Even though the sequence of porcine DP IV, amplified by RT-PCR, revealed 88% identity between both enzymes, the species-specific variations between amino acids 328 to 341 are likely to be responsible for the differences in ADA-binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14719797     DOI: 10.1515/BC.2003.172

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  Diabetes       Date:  2010-04-05       Impact factor: 9.461

2.  Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers.

Authors:  Arik Dahan; Omri Wolk; Peihua Yang; Sachin Mittal; Zhiqian Wu; Christopher P Landowski; Gordon L Amidon
Journal:  Mol Pharm       Date:  2014-11-13       Impact factor: 4.939

Review 3.  The Emerging Role of Polyphenols in the Management of Type 2 Diabetes.

Authors:  Yao Wang; Hana Alkhalidy; Dongmin Liu
Journal:  Molecules       Date:  2021-01-29       Impact factor: 4.411

4.  Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

Authors:  Su-Jin Kim; Cuilan Nian; Doris J Doudet; Christopher H S McIntosh
Journal:  Diabetes       Date:  2008-12-10       Impact factor: 9.461

5.  Analysis on conservation of disulphide bonds and their structural features in homologous protein domain families.

Authors:  Ratna R Thangudu; Malini Manoharan; N Srinivasan; Frédéric Cadet; R Sowdhamini; Bernard Offmann
Journal:  BMC Struct Biol       Date:  2008-12-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.